Literature DB >> 8114790

Multifocal motor neuropathy: electrodiagnostic features.

V Chaudhry1, A M Corse, D R Cornblath, R W Kuncl, M L Freimer, J W Griffin.   

Abstract

Diagnosis of multifocal motor neuropathy (MMN), a syndrome characterized by progressive asymmetric weakness with intact sensation, is important because the disorder often responds to treatment. Multifocal partial motor conduction block (PMCB) has been emphasized as a cardinal feature in the diagnosis of this syndrome, but detailed nerve conduction studies are not available. Nine patients, ages 28-58, had chronic, progressive, asymmetric, predominantly distal limb weakness for 5-18 years. Sensation was normal and reflexes were reduced asymmetrically. Although all 9 demonstrated PMCB localized to short nerve segments, additional features of multifocal motor demyelination were present, including temporal dispersion (5 patients), segmentally reduced motor nerve conduction velocity (7 patients), prolonged distal motor latency (4 patients), and prolonged F-wave latency (9 patients). The strength of all patients improved after treatment with human immune globulin. A reduction in the degree of PMCB or an increase in the distal motor amplitude or both accompanied the clinical improvement. These studies suggest that patients with MMN demonstrate widespread evidence of motor demyelination in addition to the well-described PMCB, and that reduction of PMCB accounts for the increase in strength following therapy.

Entities:  

Mesh:

Substances:

Year:  1994        PMID: 8114790     DOI: 10.1002/mus.880170211

Source DB:  PubMed          Journal:  Muscle Nerve        ISSN: 0148-639X            Impact factor:   3.217


  16 in total

1.  Clinical evaluation and investigation of neuropathy.

Authors:  Hugh J Willison; John B Winer
Journal:  J Neurol Neurosurg Psychiatry       Date:  2003-06       Impact factor: 10.154

2.  The effect of treatment upon temporal dispersion in IvIg responsive multifocal motor neuropathy.

Authors:  A Ghosh; A Virgincar; R Kennett; M Busby; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

3.  A practical definition of conduction block in IvIg responsive multifocal motor neuropathy.

Authors:  A Ghosh; M Busby; R Kennett; K Mills; M Donaghy
Journal:  J Neurol Neurosurg Psychiatry       Date:  2005-09       Impact factor: 10.154

4.  Peripheral neuropathy in two patients with rheumatoid arthritis receiving infliximab treatment.

Authors:  Maria G Tektonidou; John Serelis; Fotini N Skopouli
Journal:  Clin Rheumatol       Date:  2006-07-06       Impact factor: 2.980

Review 5.  Multifocal motor neuropathy.

Authors:  E Nobile-Orazio
Journal:  J Neurol Neurosurg Psychiatry       Date:  1996-06       Impact factor: 10.154

6.  Single fibre electromyography in multifocal motor neuropathy with persistent conduction blocks.

Authors:  A Lagueny; G Le Masson; P Burbeaud; P Deliac
Journal:  J Neurol Neurosurg Psychiatry       Date:  1998-09       Impact factor: 10.154

7.  Multifocal motor neuropathy: clinical and electrophysiological findings.

Authors:  A Jaspert; D Claus; H Grehl; B Neundörfer
Journal:  J Neurol       Date:  1996-10       Impact factor: 4.849

8.  Concurrence of Multifocal Motor Neuropathy and Hashimoto's Thyroiditis.

Authors:  Suk-Won Ahn; Su-Hyun Kim; Byung-Su Park; Jeong-In Cha; Sung-Min Kim; Jung-Joon Sung; Kwang-Woo Lee
Journal:  J Clin Neurol       Date:  2011-09-29       Impact factor: 3.077

9.  On the early diagnosis of IVIg-responsive chronic multifocal acquired motor axonopathy.

Authors:  Dirk Fischer; Christoph Grothe; Stephan Schmidt; Rolf Schröder
Journal:  J Neurol       Date:  2004-10       Impact factor: 4.849

10.  A trial of proficiency of nerve conduction: greater standardization still needed.

Authors:  Peter J Dyck; James W Albers; James Wolfe; Charles F Bolton; Nancy Walsh; Christopher J Klein; Andrew J Zafft; James W Russell; Karen Thomas; Jenny L Davies; Rickey E Carter; L Joseph Melton; William J Litchy
Journal:  Muscle Nerve       Date:  2013-07-17       Impact factor: 3.217

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.